Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study A Study to Assess the Use of the Somfit, an Ambulatory Electroencephalogram-Based Digital Health Technology, Compared With Polysomnography aims to compare two sleep tests in people with no symptoms or early signs of Alzheimer’s disease. It focuses on how well a mobile home-based device matches results from standard lab sleep studies and why that matters for earlier brain health tracking.
The main intervention is Somfit, a mobile EEG device used at home and in sleep labs to track brain waves, heart signals, oxygen levels, breathing, and motion. It is paired with an activity monitor and traditional in-lab polysomnography, so Lilly can see if the lighter, digital setup can stand in for heavy lab equipment in real-world use.
This is an observational study that follows a group of participants over time rather than testing a drug with random assignment. There is no blinding, and the main goal is practical learning about how accurate and useful the digital device is, not to test safety or efficacy of a new medicine.
The study is listed as not yet recruiting, signaling early-stage operational setup before patient enrollment starts. Key dates include first submission on 2026-02-05 and a recent update on 2026-03-17, pointing to active preparation, while primary and final completion dates have not yet been reported.
For investors, this update underscores Lilly’s push into digital tools around Alzheimer’s, which can support its drug portfolio by improving diagnosis and monitoring. It also places LLY in the broader race among big pharma and device firms to link wearables, sleep data, and neuro health, a theme that could support long-term valuation if the tech gains broad adoption.
The study remains in setup and has been recently updated, with further details available on the ClinicalTrials portal.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.